Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vizimpro (dacomitinib) for the Treatment of Non-Small Cell Lung Cancer

Drug Name

Vizimpro® (dacomitinib)

Developer

Pfizer

Therapy Class

Kinase inhibitor

Product Description

Epidermal growth factor receptor (EGFR) kinase inhibitor

Current Indication

Non-small cell lung cancer

Market Sector

Oncology

Development Status

Approved in the US and Japan
Expand
Close
Close
Close

Go Top